ABUS

Arbutus Biopharma Corporation

Price

$4.35

return (12m)

p/e

5.66

p/bv

3.50

DIVIDEND YIELD

0.00%

ABUS price

Arbutus Biopharma

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ABUS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals ABUS

Valuation

P/E

5.66

Sector -4.15

Industry -4.15

P/BV

3.50

Sector 2.06

Industry 2.06

P/Revenue (PSR)

4.75

Sector -4.16

Industry -4.16

EV/EBITDA

4.80

Sector -241.86

Industry -241.86

EV/EBIT

4.80

Sector -671.75

Industry -671.75

P/EBITDA

5.66

Sector -4.30

Industry -4.30

P/EBIT

5.66

Sector -4.35

Industry -4.35

P/Total Assets

3.28

Sector 1.46

Industry 1.46

P/Net Current Assets

3.50

Sector -12.67

Industry -12.67

P/Working Capital

3.35

Sector -12.58

Industry -12.58

EPS

0.83

Sector -2.19

Industry -2.19

BVPS

1.34

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

100.00%

Sector 36.44%

Industry 36.44%

EBITDA Margin

94.75%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

94.74%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

81.01%

Sector -38.78%

Industry -38.78%

Net Profit Margins

83.94%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.65

Sector 0.03

Industry 0.03

Profitability

ROE

61.77%

Sector -67.01%

Industry -67.01%

ROA

57.98%

Sector -66.28%

Industry -66.28%

ROIC

755.59%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

54.21

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-0.56

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

-0.56

Sector -3.79

Industry -3.79

Net Debt / Equity

-0.37

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.94

Sector 0.42

Industry 0.42

Liabilities/Assets

0.06

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

77.10%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Arbutus Biopharma ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$4.35

Fair Value

$5.00

Upside Return potential.

15.00%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ABUS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ABUS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Arbutus Biopharma

Arbutus Biopharma Corporation

Average Investor10 user rating

4.0 (0 people)

States of America

21 years

Founded: 2005

2007

Time since IPO - 19 years

78

Employees

Arbutus Biopharma Corporation (States of America) is listed on the Nasdaq and has a market capitalization of $909.86 million, with shareholders equity totaling $260.18 million.

The company employs approximately 78 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, Arbutus Biopharma Corporation reported $191.45 million in revenue, generating net income of $160.71 million.

Key financial metrics include a P/E ratio of 5.66, a price-to-book (P/B) ratio of 3.50, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ABUS.

Market cap

$909.86 million

Net worth

$260.18 million

$260,180,000.00

Assets

$277.16 million

$277,160,000.00

Total Shares Outstanding

194.00 million

194,000,000

Average Daily Trading Volume

$2.12 million

$2,119,931.70

Sector

Healthcare

Industry

Biotecnologia

ABUS

ABUS revenue and profits

Financial Results ABUS

DRAG THE FRAME TO SEE MORE DATA

ABUS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14